The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 7, 2013, Pages

  Shah, Payal ^a   Ardestani, Amin ^a   Dharmadhikari, Gitanjali ^a   Laue, Svenja ^a   Schumann, Desiree M ^b   Kerr Conte, Julie ^c   Pattou, Francois ^c   Klein, Thomas ^b   Maedler, Kathrin ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROTYROSINE; GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; LINAGLIPTIN; PALMITIC ACID;

ARTICLE; CELL PROTECTION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN STABILITY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CELL SURVIVAL; CYTOKINES; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG INVERSE AGONISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; PALMITIC ACID; PEPTIDE FRAGMENTS; PROTEIN STABILITY; PURINES; PYRAZINES; QUINAZOLINES; RECOMBINANT PROTEINS; TISSUE CULTURE TECHNIQUES; TRIAZOLES;

EID: 84879919203     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1029     Document Type: Article

References (59)

1. Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829-835. (Pubitemid 23188160)
2. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705. (Pubitemid 46048557)
3. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29:46-52. (Pubitemid 16162741)
4. Lambeir AM, Scharpe S, De Meester I. DPP4 inhibitors for diabetes-what next? Biochem Pharmacol. 2008;76:1637-1643.
5. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150-156.
6. Foley JE, Bunck MC, Moller-Goede DL, et al. β-Cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia. 2011; 54:1985-1991.
7. Brubaker PL, Drucker DJ. Minireview: glucagon-like peptides regulate cell proliferation and apoptosis in the pancreas, gut, and central nervous system. Endocrinology. 2004;145:2653-2659. (Pubitemid 38686211)
8. Li L, El-Kholy W, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects β cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia. 2005;48:1339-1349. (Pubitemid 41186100)
9. Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741-748. (Pubitemid 30339989)
10. Bulotta A, Hui H, Anastasi E, et al. Cultured pancreatic ductal cells undergo cell cycle re-distribution and β-cell-like differentiation in response to glucagon-like peptide-1. J Mol Endocrinol. 2002;29:347-360. (Pubitemid 36024549)
11. Buteau J, El-Assaad W, Rhodes CJ, et al. Glucagon-like peptide-1 prevents β cell glucolipotoxicity. Diabetologia. 2004;47:806-815. (Pubitemid 38756992)
12. Cechin SR, Perez-Alvarez I, Fenjves E, et al. Anti-inflammatory properties of exenatide in human pancreatic islets. Cell Transplant. 2012;21(4):633-648.
13. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149-5158. (Pubitemid 37476040)
14. Lupi R, Mancarella R, Del Guerra S, et al. Effects of exendin-4 on islets from type 2 diabetes patients. Diabetes Obes Metab. 2008;10:515-519. (Pubitemid 351639096)
15. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003;52:741-750. (Pubitemid 36323582)
16. Cho JM, Jang HW, Cheon H, et al. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Diabetes Res Clin Pract. 2011;91:72-79.
17. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA. Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic- hyperinsulinemic clamp study. Diabetes. 2002;51:2677-2683. (Pubitemid 34970918)
18. Eckhardt M, Langkopf E, Mark M, et al. 8-[3-(R)-aminopiperidin-1-yl]-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin -2-ylmethyl)- 3,7-dihydropurine-2,6- dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem. 2007;50:6450-6453. (Pubitemid 350309082)
19. Forst T, Uhlig-Laske B, Graefe-Mody U, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010;27:1409-1419.
20. Sauter NS, Schulthess FT, Galasso R, Castellani LW, Maedler K. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia. Endocrinology. 2008;149:2208-2218. (Pubitemid 351574505)
21. Maedler K, Sergeev P, Ris F, et al. Glucose-induced β-cell production of interleukin-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851-860.
22. Kerr-Conte J, Vandewalle B, Moerman E, et al. Upgrading pretransplant human islet culture technology requires human serum combined with media renewal. Transplantation. 2010;89:1154-1160.
23. Schulthess FT, Paroni F, Sauter NS, et al. CXCL10 impairs β cell function and viability in diabetes through TLR4 signaling. Cell Metab. 2009;9:125-139.
24. Kaiser N, Corcos AP, Sarel I, Cerasi E. Monolayer culture of adult rat pancreatic islets on extracellular matrix: modulation of B-cell function by chronic exposure to high glucose. Endocrinology. 1991; 129:2067-2076.
25. Maedler K, Spinas GA, Dyntar D, et al. Distinct effects of saturated and monounsaturated fatty acids on β-cell turnover and function. Diabetes. 2001;50:69-76. (Pubitemid 32047983)
26. Le Bacquer O, Shu L, Marchand M, et al. TCF7L2 splice variants have distinct effects on β-cell turnover and function. Hum Mol Genet. 2011;20:1906-1915.
27. Ceriello A, Mercuri F, Quagliaro L, et al. Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress. Diabetologia. 2001;44:834-838. (Pubitemid 32642455)
28. Marchetti P, Del Guerra S, Marselli L, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab. 2004;89:5535-5541. (Pubitemid 39518437)
29. Sokolovsky M, Riordan JF, Vallee BL. Tetranitromethane. A reagent for the nitration of tyrosyl residues in proteins. Biochemistry. 1966;5:3582-3589.
30. Xu G, Kaneto H, Laybutt DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56:1551-1558. (Pubitemid 46842610)
31. Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired β-cell function. Hum Mol Genet. 2009;18:2388-2399.
32. Serre V, Dolci W, Schaerer E, et al. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3′,5′-monophosphate levels and β-cell glucose competence. Endocrinology. 1998;139:4448-4454. (Pubitemid 28487758)
33. Waget A, Cabou C, Masseboeuf M, et al. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology. 2011;152:3018-3029.
34. Liu Z, Stanojevic V, Avadhani S, Yano T, Habener JF. Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances β cell survival. Diabetologia. 2011;54:2067-2076.
35. Proost P, Struyf S, Schols D, et al. Processing by CD26/dipeptidyl- peptidase IV reduces the chemotactic and anti-HIV-1 activity of stromal-cell-derived factor-1α. FEBS Lett. 1998;432:73-76. (Pubitemid 28360743)
36. Liu Z, Habener JF. Stromal cell-derived factor-1 promotes survival of pancreatic β cells by the stabilisation of β-catenin and activation of transcription factor 7-like 2 (TCF7L2). Diabetologia. 2009;52:1589-1598.
37. Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab. 2011;13:258-267.
38. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65-74.
39. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:653-661.
40. De Meester I, Durinx C, Bal G, et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol. 2000;477:67-87. (Pubitemid 32173991)
41. Maedler K, Dharmadhikari G, Schumann DM, Storling J. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes. Handb Exp Pharmacol. 2011;257-278.
42. Portha B, Tourrel-Cuzin C, Movassat J. Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient β-cell mass. Exp Diabetes Res. 2011;2011:376509.
43. D'Aleo V, Del Guerra S, Filipponi F, et al. The direct effects of DPP-4 inhibition on isolated human islets include protection from glucotoxicity. Diabetologia. 2009;52:S35-S36.
44. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and α cells. Nat Med. 2011;17:1481-1489.
45. Marchetti P, Bugliani M, Kirkpatrick CL, et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia. 2012;55:3262-3272.
46. Whalley NM, Pritchard LE, Smith DM, White A. Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells? J Endocrinol. 2011;211:99-106.
47. Hansen AM, Bodvarsdottir TB, Nordestgaard DN, et al. Upregulation of α cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus-an adaptive response to hyperglycaemia? Diabetologia. 2011;54:1379-1387.
48. Kirkpatrick CL, Marchetti P, Purrello F, et al. Type 2 diabetes susceptibility gene expression in normal or diabetic sorted human α and β cells: correlations with age or BMI of islet donors. PLoS One. 2010;5:e11053.
49. Chepurny OG, Holz GG. Over-expression of the glucagon-like peptide-1 receptor on INS-1 cells confers autocrine stimulation of insulin gene promoter activity: a strategy for production of pancreatic β-cell lines for use in transplantation. Cell Tissue Res. 2002;307:191-201. (Pubitemid 34158531)
50. Cheong YH, Kim MK, Son MH, Kaang BK. Glucose exposure pattern determines glucagon-like peptide 1 receptor expression and signaling through endoplasmic reticulum stress in rat insulinoma cells. Biochem Biophys Res Commun. 2011;414:220-225.
51. Pala L, Mannucci E, Pezzatini A, et al. Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun. 2003;310:28-31. (Pubitemid 37162757)
52. Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia. 2011;54:10-18.
53. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired β-cell function? Diabetes. 2010;59:1117-1125.
54. Mussig K, Staiger H, Machicao F, Haring HU, Fritsche A. Genetic variants affecting incretin sensitivity and incretin secretion. Diabetologia. 2010;53:2289-2297.
55. Ryskjaer J, Deacon CF, Carr RD, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol. 2006;155:485-493. (Pubitemid 44463956)
56. Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005;48:1168-1172. (Pubitemid 40909653)
57. Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP-4 inhibitors-from preclinical development to clinical research. Kidney Blood Press Res. 2012;36:65-84.
58. Meneilly GS, Demuth HU, McIntosh CH, Pederson RA. Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabet Med. 2000;17:346-350. (Pubitemid 30353798)
59. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917-1925.